MISTIC 12-Month Follow-Up: What the 2026 Translational Psychiatry Paper Actually Shows

Definition box

Definition: The MISTIC 12-month follow-up is the prospective long-term extension of Stanford-affiliated magnesium–ibogaine therapy (MISTIC) published in *Translational Psychiatry* (2026; doi: 10.1038/s41398-026-04327-5). It reports durability of symptom and disability signals through 12 months after the original open-label protocol in special-operations veterans with traumatic brain injury (TBI) history: 25 of 30 treated participants completed 12-month assessments. Psychoactive ibogaine in the parent protocol was oral; IV magnesium was support, not psychoactive ibogaine. This follow-up is not a randomized controlled trial and not proof that physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine) works. Authors note important confounders—including other psychedelics and interventions during follow-up. Cardiac QTc risk remains central. Ibogaine is U.S. Schedule I and not FDA-approved.

Quotable answer (58 words)

The 2026 Translational Psychiatry MISTIC 12-month follow-up found durable symptom and disability improvements in 25 of 30 veterans after oral ibogaine plus IV magnesium support—not a controlled trial of psychoactive IV ibogaine infusion. Confounders such as other psychedelics during follow-up limit causal claims. RCTs are still needed. Ibogaine can prolong QTc and is not FDA-approved.

Why this paper-spoke exists

Searchers often ask: “Did Stanford prove ibogaine lasts a year?” Headlines about durable MISTIC outcomes are easy to compress into cure or IV-proof marketing. This page keeps the paper named, the route labeled, and the evidence gap honest.

Related reading: /blog/stanford-ibogaine-mistic · /blog/ibogaine-for-tbi-veterans · Entity hub: /what-is-ibogaine-infusion · Oral vs IV: /blog/ibogaine-oral-vs-iv.

What was studied

| Feature | Accurate description | |---------|----------------------| | Citation | Prospective long-term follow-up of MISTIC; *Translational Psychiatry* 2026; doi 10.1038/s41398-026-04327-5 | | Parent study | Cherian et al., *Nature Medicine* 2024 — open-label oral ibogaine + IV magnesium in ~30 special-operations veterans with TBI history | | Design | Prospective observational follow-up at ~3, 6, 9, and 12 months | | Completers | 25 / 30 completed 12-month assessments | | Population | Male U.S. Special Operations Veterans with TBI-related functional/psychiatric burden (per parent protocol framing) | | Psychoactive route | Oral ibogaine (parent protocol) | | IV component | IV magnesium support — not psychoactive IV ibogaine | | Outcomes framed | Functional disability (self-report) + clinician-administered PTSD, depression, anxiety measures | | What it is not | IV-psychoactive ibogaine RCT; FDA approval package; addiction-cure evidence; license to skip screening |

Readers should open the primary paper for exact instruments, effect sizes, adverse-event reporting, and limitation language rather than relying on secondary blogs.

Methods (plain language)

Researchers followed the same naturalistic MISTIC cohort after the initial open-label treatment window reported in *Nature Medicine* 2024. Participants completed baseline and post-treatment assessments, then returned for scheduled long-term check-ins through one year. Analytic approaches described in the paper include linear mixed-effects models for symptom trajectories and survival-style estimates of sustained remission among those who remitted soon after treatment.

Important design features for non-specialist readers:

1. No randomization / no placebo control in the parent treatment assignment.
2. Open-label expectations can inflate apparent benefit.
3. Small N — 30 treated; 25 with 12-month data.
4. Special population — highly selected special-operations veterans; results do not automatically generalize.
5. Naturalistic year — real life (other care, other substances, life events) continues after discharge.

Key findings (no hype)

Reported signals in the follow-up abstract/paper narrative include:

• Sustained reductions in disability, PTSD, depression, and anxiety symptom measures through 12 months in this cohort, with large effect-size estimates at 12 months relative to baseline (paper reports Cohen’s *d* ≥ 2.18 at 12 months for key domains).
• Among participants who remitted immediately post-treatment, estimated probabilities of remaining in remission at 12 months on the order of ~84% PTSD, ~66% depression, ~61% anxiety (survival analyses as reported).
• Authors themselves highlight that most participants reported other psychedelic use or other interventions during follow-up, which must temper causal attribution to a single ibogaine exposure.

Honest reading: durable *observed trajectories* in an open-label veteran cohort are scientifically interesting and motivate RCTs. They are not proof of a cure, not population-average “success rates” for clinics to advertise, and not evidence for psychoactive IV ibogaine.

Limits and confounders

| Confounder / limit | Why it matters | |--------------------|----------------| | Open-label parent design | Expectancy, placebo, and non-blinded ratings | | Concurrent psychedelics / interventions (~majority in follow-up) | Symptom change may reflect multi-exposure journeys, not ibogaine alone | | Attrition (5/30 without full 12-mo data) | Completers may differ from non-completers | | Selection effects | Motivated, screened veterans ≠ all TBI or PTSD patients | | Complementary modalities in MISTIC narrative | Program structure, travel, and adjunct care can drive change | | Route mismatch for this brand | Oral + IV Mg ≠ psychoactive IV ibogaine infusion | | Cardiac literature still applies | QTc risk is not “solved” by a hopeful year of scores |

Systematic reviews (Köck 2022; Mosca 2023) already stress limited RCTs and cardiotoxicity concerns across ibogaine clinical literature.

Route honesty: oral ≠ psychoactive IV

MISTIC remains the clearest public teaching case:

• Oral ibogaine = psychoactive dose in the studied protocol
• IV magnesium = cardiac-support framing, not the psychoactive alkaloid by vein
• IV ibogaine infusion (this site’s entity) = physician-supervised psychoactive intravenous ibogaine

Clinics that say “we run the Stanford 12-month IV protocol” should be asked in writing: Is ibogaine intravenous, or only magnesium/fluids? See /blog/how-to-choose-an-ibogaine-clinic and /blog/magnesium-ibogaine-cardiac-protocol.

Cardiac / YMYL context

Even with magnesium co-administration narratives, ECG screening, electrolyte management, telemetry culture, and emergency readiness remain non-negotiable teaching points. Oral-route QTc data from Knuijver et al. (*Addiction*, 2021) show mean QTc prolongation on the order of ~95 ms and half of subjects exceeding 500 ms after 10 mg/kg oral ibogaine HCl in a small monitored sample—still serious risk teaching for any route discussion (/blog/knuijver-2021-ibogaine-qtc-safety, /blog/ibogaine-mortality-cardiac-risk, /safety-and-screening).

IV magnesium support ≠ eliminated arrhythmia risk.

What this does NOT prove for IV ibogaine infusion brand

| Claim someone might make | Accurate status | |--------------------------|-----------------| | “12-month MISTIC proves IV ibogaine works” | False — oral + IV Mg; observational | | “84% PTSD remission forever for everyone” | False — conditional survival estimate in remitted subset of a small open-label cohort; confounders | | “FDA-approved for veterans TBI” | False — Schedule I; not FDA-approved | | “Skip cardiac screening because magnesium” | Dangerous and false | | Adjacent literature with route labels OK? | Yes — if labeled oral+IV Mg, open-label, small N, RCTs needed |

Soft CTA

If the 12-month MISTIC headlines prompted questions about physician-supervised IV ibogaine infusion, start with route literacy and cardiac diligence: /safety-and-screening. Request a confidential screening consult via /apply only after evidence-gap education—not after cure headlines. Parent study spoke: /blog/stanford-ibogaine-mistic. Veterans/TBI context: /blog/ibogaine-for-tbi-veterans.

FAQ

What is the MISTIC 12-month follow-up paper? A 2026 *Translational Psychiatry* prospective follow-up of the open-label magnesium–ibogaine (MISTIC) veteran/TBI cohort, with 25 of 30 completing 12-month assessments. Oral ibogaine + IV magnesium support—not psychoactive IV ibogaine.

Did symptoms stay better at one year? The paper reports durable observed improvements in disability and psychiatric measures in this naturalistic cohort. Confounders (including other psychedelics/interventions) limit causal certainty. RCTs are still needed.

Was ibogaine given by IV in MISTIC? No. Ibogaine was **oral**; magnesium was **IV** support.

Does 25/30 prove IV ibogaine infusion works? No. Different route, open-label design, small N, special population.

Why do authors mention other psychedelics? Because most participants reported other psychedelic use or other interventions during follow-up—so year-long trajectories cannot be attributed to ibogaine alone.

Is this FDA approval for veterans? No. Ibogaine remains Schedule I in the U.S. and is not FDA-approved.

Should cardiac screening still happen? Yes. QTc risk teaching still applies (/safety-and-screening).

Where is the original Nature Medicine MISTIC spoke? /blog/stanford-ibogaine-mistic.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Cherian/MISTIC 12-month follow-up is open-label oral ibogaine + IV magnesium durability data—not psychoactive IV ibogaine proof.

Sources (selected)

1. Cherian K.N. et al. (follow-up authorship as published). Is ibogaine treatment durable? 12-month follow-up of magnesium–ibogaine therapy (MISTIC) in special operations veterans with traumatic brain injuries. *Translational Psychiatry*. 2026. doi: 10.1038/s41398-026-04327-5. (Prospective follow-up; n=25/30; oral ibogaine + IV Mg; confounders noted; not IV-psychoactive proof.)
2. Cherian K.N. et al. Magnesium–ibogaine therapy in veterans with traumatic brain injuries. *Nature Medicine*. 2024. doi: 10.1038/s41591-023-02705-w. PMID: 38182784. (Parent open-label oral + IV Mg; n≈30.)
3. Knuijver T. et al. Safety of ibogaine administration in detoxification of opioid-dependent individuals. *Addiction*. 2021. doi: 10.1111/add.15448. (Oral QTc signals.)
4. Köck P. et al. A systematic literature review of clinical trials and therapeutic applications of ibogaine. *Journal of Substance Abuse Treatment*. 2022. doi: 10.1016/j.jsat.2021.108717.
5. Mosca A. et al. Ibogaine/noribogaine in the treatment of substance use disorders: a systematic review. *Current Neuropharmacology*. 2023. doi: 10.2174/1570159X21666221017085612.
6. 21 CFR 1308.11 — ibogaine Schedule I (United States).